Affymax (AFFY +2.4%) says it received a $50M development-milestone payment from Takeda...

|By:, SA News Editor

Affymax (AFFY +2.4%) says it received a $50M development-milestone payment from Takeda Pharmaceutical (TKPYY.PK), triggered by the FDA's approval of its Omontys anemia drug late last month.